In English | En español
Questions About Cancer? 1-800-4-CANCER

Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)

  • Last Modified: 06/06/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Stage Information for Childhood Extracranial GCTs

Nonseminoma Testicular GCT Staging From the COG
Ovarian GCT Staging From the COG
Ovarian GCT Staging From the FIGO
Extragonadal Extracranial GCT Staging From the COG

As with other childhood solid tumors, stage directly impacts the outcome of patients with malignant germ cell tumors (GCTs).[1-3] The most commonly used staging systems in the United States are as follows:[4]

Nonseminoma Testicular GCT Staging From the COG
  • Stage I: Limited to testis; complete resection by high inguinal orchiectomy or transscrotal resection with no tumor spillage. There must be no evidence of disease beyond the testis by radiologic scans or pathology.

  • Stage II: Transscrotal orchiectomy with spillage of tumor; microscopic disease in scrotum or high in spermatic cord (>0.5 cm). Tumor markers fail to normalize or increase.

  • Stage III: Gross residual disease; retroperitoneal lymph node involvement (>2 cm in boys younger than 10 years).

  • Stage IV: Distant metastases, including liver, brain, bone, and lung.

Retroperitoneal lymph node dissection has not been required in pediatric germ cell trials to stage disease in males younger than 15 years. Data on adolescent males with testicular GCTs are limited. Retroperitoneal lymph node dissection is used for both staging and treatment in adult testicular GCT trials.[5] (Refer to the PDQ summary on Testicular Cancer Treatment for more information about the staging of adult testicular GCTs.)

Ovarian GCT Staging From the COG
  • Stage I: Localized disease; completely resected without microscopic disease in the resected margins or evidence of capsular rupture. Negative peritoneal cytology.

  • Stage II: Microscopic residual disease, capsular invasion, or microscopic lymph node involvement.

  • Stage III: Gross residual disease, gross lymph node involvement (>2 cm), or cytologic evidence of tumor cells in ascites.

  • Stage IV: Disseminated disease involving lungs, liver, brain, or bone.

Ovarian GCT Staging From the FIGO

Another ovarian GCT staging system used frequently by gynecologic oncologists is the FIGO staging system, which is based on an adequate staging operation at the time of diagnosis.[6] (Refer to the PDQ summary on Ovarian Germ Cell Tumors Treatment for more information.) This system has also been used by some pediatric centers [2] and is as follows:

Stage I: Tumor limited to the ovaries

  • IA: One ovary, no ascites, intact capsule.
  • IB: Both ovaries, no ascites, intact capsule.
  • IC: Ruptured capsule, capsular involvement, positive peritoneal washings, or malignant ascites.

Stage II: Ovarian tumor with pelvic extension

  • IIA: Pelvic extension to uterus or tubes.
  • IIB: Pelvic extension to other pelvic organs (bladder, rectum, or vagina).
  • IIC: Pelvic extension, plus findings indicated for stage IC.

Stage III: Tumor outside the pelvis, or positive nodes

  • IIIA: Microscopic seeding outside the true pelvis.
  • IIIB: Gross deposit 2 cm or smaller.
  • IIIC: Gross deposits larger than 2 cm or positive nodes.

Stage IV: Distant organ involvement, including liver parenchyma or pleural space

Extragonadal Extracranial GCT Staging From the COG
  • Stage I: Localized disease; complete resection with no microscopic disease at margins or in regional lymph nodes. Tumor markers must normalize in appropriate half-life after resection. Complete coccygectomy for sacrococcygeal site.

  • Stage II: Microscopic residual disease, capsular invasion, and/or microscopic lymph node involvement. Tumor markers fail to normalize or increase.

  • Stage III: Gross residual disease and gross lymph node involvement (>2 cm).

  • Stage IV: Distant metastases, including liver, brain, bone, or lung.

References
  1. Ablin AR, Krailo MD, Ramsay NK, et al.: Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group. J Clin Oncol 9 (10): 1782-92, 1991.  [PUBMED Abstract]

  2. Mann JR, Pearson D, Barrett A, et al.: Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 63 (9): 1657-67, 1989.  [PUBMED Abstract]

  3. Marina N, Fontanesi J, Kun L, et al.: Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer 70 (10): 2568-75, 1992.  [PUBMED Abstract]

  4. Brodeur GM, Howarth CB, Pratt CB, et al.: Malignant germ cell tumors in 57 children and adolescents. Cancer 48 (8): 1890-8, 1981.  [PUBMED Abstract]

  5. de Wit R, Fizazi K: Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24 (35): 5482-92, 2006.  [PUBMED Abstract]

  6. Cannistra SA: Cancer of the ovary. N Engl J Med 329 (21): 1550-9, 1993.  [PUBMED Abstract]